Monograph
C10AB02 - Bezafibrate |
Propably not porphyrinogenic |
PNP |
Rationale
Substrate of CYP 3A4. Two references stating non-porphyrinogenicity. Occasional clinical experience of non-porphyrinogenicity
Chemical description
Cholesterol lowering clofibrate derivative, dose 600 mg/d. 95 % absorbed from the gut. Metabolized by CYP 3A4 . No data pointing to CYP-induction. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=3): tolerated. South African list: use with care French list: authorized
IPNet drug reports
Uneventful use reported in 9 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Norway
Luxembourg
Finland© NAPOS 2024